Invariant Natural Killer T cells complexed with Dendritic cells are a potent anti-tumor stimulus/

Administration of iNKT-DC complexes to mice with a xenograft B cell lymphoma stimulated efficient CD8+ T cell-mediated tumor regression. “CD8+ T-cell Antitumor Immunity via Human iNKT–DC Conjugates” Dana C. Baiu, Jenny E. Gumperz, et al. Cancer Immunol Res (2026) 14 (2): 318–334. PMID: 41236542 PMCID: PMC12716482 DOI: 10.1158/2326-6066.CIR-25-0454 Related Ancell Products anti-CD69 mAb

Invariant Natural Killer T cells complexed with Dendritic cells are a potent anti-tumor stimulus/ Read More »

Purification of EV may not be necessary to analyze surface markers using microarray

This Danish research group utilized Ancell anti-tetraspanin biotinylated mAbs to detect purified and unpurified EVs from ischemic stroke patient plasma captured on microarray. “Direct Profiling of Extracellular Vesicle Surface Markers in Plasma: A Proof-of-Concept Study” Lee-Ann Clegg, Malene Möller Jörgensen, et al. Biol Cell 2025 Dec;117(12):e70047. doi: 10.1111/boc.70047 PMID: 41420477 Related Ancell Products anti-CD9 anti-CD63

Purification of EV may not be necessary to analyze surface markers using microarray Read More »

CAR T cell efficacy improved by engineered expression of OX40(CD134)

OX40(CD134) expression on CAR T cell surface improves anti-tumor activity in a mouse model. “OX40–heparan sulfate binding facilitates CAR T cell penetration into solid tumors in mice” Huihui Zhang, Xuanming Yang, et al. (18 June 2025) Science Translational Medicine 17(803):eadr2151. doi: 10.1126/scitranslmed.adr2151. Epub 2025 Jun 18. PMID: 405 Related Ancell Products anti-human CD134(OX40) mAb anti-human

CAR T cell efficacy improved by engineered expression of OX40(CD134) Read More »

Humanized Mice Reviewed

Authors review utilization of various types of humanized mice to study human immunological mechanisms. Challenges include engineering humanized populations of Neutrophils, Red Blood Cells, Hepatocytes, and resident Skin macrophages. They cite and recommend multi-omic canonical correlations of human vs humanized mouse biomarkers to assess the utility of these technologies. “Engineering Mice to Study Human Immunity”

Humanized Mice Reviewed Read More »

Treatments for IgA-nephropathy reviewed

IgA Nephropathy is one of the leading causes of kidney failure worldwide. It is caused by production of IgA1 antibodies lacking galactose in their o-Glycan regions, which cause them to be auto antigenic and can lead to protein aggregates. Traditional treatments have been limited to kidney care lifestyle modification and high-dose long term glucocordicosteroids. More

Treatments for IgA-nephropathy reviewed Read More »

Targeting CD19 expression can overcome relapses in autoimmune patients treated with CD20 targeted therapy

“Can autoimmune disease be cured by deep CD19+ cell depletion?” Dan Suan, John Moore, Christopher C Goodnow. J Immunol. 2025 Jun 1;214(6):1075-1092. doi: 10.1093/jimmun/vkaf008. PMID: 40116909 The Authors review encouraging data from B cell autoimmune patients in relapse after CD20 treatments who were given CD19 CAR T cell treatment, or blinumomab anti-CD19 bispecific T cell

Targeting CD19 expression can overcome relapses in autoimmune patients treated with CD20 targeted therapy Read More »

TRBC1 specific Immunotherapy showing promise for T cell Lymphoma treatment

Autolus Therapeutics tested the toxicity and efficacy of AUTO4, a TRBC1 specific CAR cell therapeutic on 10 relapsed/refractory T cell lymphoma patients. This treatment appears to be safe with only minimal toxicity. The CAR T cells were shown to be residing in the majority of patient lymph nodes.Ancell anti-TRBC1/Biotin (clone Jovi-1) was used to sort

TRBC1 specific Immunotherapy showing promise for T cell Lymphoma treatment Read More »

SARS COV2 mRNA extended dose interval yielded improved B cell response but no difference in T cell response

Recipients who received 2nd Covid booster with a longer than recommended interval from 1st immunization had improved specific antibody response, but asimilar T cell response. This differential effect was nullified by a 3rdbooster. “Improved antibody breadth with an extended primary dose interval of COVID-19 vaccine is overcome by boosters” JI Ahmed, CM Card, et al.

SARS COV2 mRNA extended dose interval yielded improved B cell response but no difference in T cell response Read More »